Overall, these results suggested that ERCC6L accelerates the G2/M phase transition of BC cells by regulating the p53/p21/CDK1/Cyclin B and Aurora A/PLK/CDC25C/CDK1/Cyclin B pathways. Here, ERCC6L is linked to breast cancer.